Clinical trial recommends methotrexate for children with severe atopic dermatitis

  • 📰 medical_xpress
  • ⏱ Reading Time:
  • 40 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 51%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

A study led by King's College London compared the safety and efficacy of ciclosporin with methotrexate in children and young people with severe atopic dermatitis, a debilitating skin condition. They also examined whether the severity of the disease changed or returned after treatment ended.

for pediatric patients with this condition, and with new therapies being introduced at a high cost, establishing a gold standard for treatment with the conventional systemic therapies like methotrexate and ciclosporin is needed.

The trial assessed 103 children with severe atopic dermatitis age 2–16 years across 13 centers in the U.K. and Ireland. The patients were given oral doses of methotrexate or ciclosporin and assessed over nine months of treatment and six months after the therapy ended. The study found that ciclosporin works faster and reduces disease severity more at 12 weeks but was more expensive, whereas methotrexate was significantly cheaper and led to better objective disease control after 12 weeks and off therapy, with fewer participant-reported flares of atopic dermatitis after treatment had stopped. There were also no concerning safety signals.

The paper,"Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 101. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Research team leads adaptive, efficient multi-arm phase 2 clinical trial for glioblastomaAn innovative phase 2 clinical trial led by Dana-Farber Cancer Institute, in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma, has reported initial results in the Journal of Clinical Oncology. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that benefit patients.
Source: medical_xpress - 🏆 101. / 51 Read more »

Li-Fraumeni Syndrome: Woman with rare condition given clinical trial hopeElla Hines, 24, has Li-Fraumeni Syndrome, which increases her chances of getting cancer by 90%.
Source: bbcemt - 🏆 120. / 51 Read more »